anti-inflammatory drug – Communicable Diseases Research

Non-steroidal anti-inflammatory drugs and clinical outcomes in patients with COVID-19

Article

Published on 2022-10-172022-11-16
Journal: Frontiers in Cellular and Infection Microbiology [Category] meta-analysis,

A novel platform for attenuating immune hyperactivity using EXO-CD24 in COVID-19 and beyond

Article

Published on 2022-09-072022-10-06
Journal: EMBO Molecular Medicine [Category] 진단,

Atorvastatin for reduction of 28-day mortality in hospitalized COVID-19 patients: study protocol for a randomized, double-blinded, placebo-controlled, clinical trial

입원한 COVID-19 환자의 28일 사망률 감소를 위한 아토르바스타틴: 무작위, 이중 맹검, 위약 대조, 임상 시험을 위한 연구 프로토콜

Article

Published on 2022-08-082022-09-11
Journal: Trials [Category] SARS, 임상,

[키워드] 28-day mortality 95% confidence interval Acute kidney injury added adjusted odds ratio All participants all-cause mortality anti-inflammatory drug approval assigned atorvastatin being clinical Clinical improvement clinical trial clinician Consequences Consistency coronavirus COVID-19 COVID-19 patient Delta disease double-blinded drug events healthcare worker Hmg coa hospital hospitalized COVID-19 hospitalized patients In-hospital in-hospital mortality Informed consent institutional review board intensive care isolation hospital logistic regression model mass vaccination mechanical ventilation Mortality neurological once daily P-value pandemic pandemic era participant Patient performed Placebo placebo-controlled Primary outcome protocol Psychological Randomized randomized clinical trial Randomized controlled trial receive recruited reduce mortality reduced reduction Registered registry Research SARS-CoV-2 Sepsis severity severity of COVID-19 standard treatment statins Study protocol supported Tablet the patient university vaccination
[DOI] 10.1186/s13063-022-06619-9 PMC 바로가기 [Article Type] Article

In-silico screening and in-vitro assay show the antiviral effect of Indomethacin against SARS-CoV-2

In-silico 스크리닝 및 in-vitro assay는 SARS-CoV-2에 대한 Indomethacin의 항바이러스 효과를 보여줍니다

Article

Published on 2022-08-012022-09-11
Journal: Computers in biology and medicine [Category] COVID19(2023년), SARS, 신약개발, 치료제,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus Analysis analyzed anti-inflammatory drug Antiviral effect applied can be used caused cellular Comparative Compound compounds Computational drug coronavirus coronavirus disease COVID-19 CTD death Differential gene expression drug drug candidate drug candidates Drug repurposing epithelial cell epithelial cells Gene Expression Host host response human cell human cells human lung human lung epithelial cells humans in-silico In-vitro in-vitro assay indomethacin Infection investigated moderate molecules mRNA expression profile nonsteroidal anti-inflammatory drug Perspective Protein responsible SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 Spread tested the SARS-CoV-2 therapeutic Toxicogenomics treat Treatment Vaccine Vero CCL-81 cell Vero CCL-81 cells viral infection Virtual screening Vitamin was performed
[DOI] 10.1016/j.compbiomed.2022.105788 PMC 바로가기 [Article Type] Article

Effects of non-steroidal anti-inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVID-19

비스테로이드성 소염제 및 기타 에이코사노이드 경로 조절제가 항바이러스 및 알레르기 반응에 미치는 영향: COVID-19 시대의 에이코사노이드 합의 보고서에 대한 EAACI 태스크포스

Article

Published on 2022-08-012022-09-11
Journal: Allergy [Category] COVID19(2023년), SARS, 치료제,

[키워드] allergic allergic diseases allergic inflammation allergy analgesic effect antagonist Anti-inflammatory anti-inflammatory drug Antipyretic Antiviral applied Asthma Biologicals biologicals. cannabinoids chronic inflammatory disease Consensus COVID-19 COVID-19 treatment Effect eicosanoid General population Horizon identify Inflammation Inflammatory diseases Interaction knowledge leukotriene leukotriene receptor antagonist leukotriene receptor antagonists LTRA mechanism mechanism of action medication medications NERD non-steroidal anti-inflammatory drug Non-steroidal anti-inflammatory drugs NSAID NSAIDS pandemic of COVID-19 pathway Pathways predict prostaglandin prostaglandin D2 Research Respiratory disease respiratory infections response SARS-CoV-2 selectivity Symptom therapy Treatment unmet need viral infection viral infections
[DOI] 10.1111/all.15258 PMC 바로가기 [Article Type] Article

Targeting autophagy regulation in NLRP3 inflammasome-mediated lung inflammation in COVID-19

Review article

Published on 2022-08-012022-10-05
Journal: Clinical immunology (Orlando, Fla.) [Category] SARS, 임상, 치료제,

Non-steroidal anti-inflammatory drugs in the era of the Covid-19 pandemic in the context of the human and the environment

Review article

Published on 2022-08-012022-10-05
Journal: The Science of the total environment [Category] COVID19(2023년), SARS, 치료제,

The effect of reparixin on survival in patients at high risk for in-hospital mortality: a meta-analysis of randomized trials

병원 내 사망 위험이 높은 환자의 생존에 대한 레파릭신의 효과: 무작위 시험의 메타 분석

Meta-Analysis

Published on 2022-07-252022-09-11
Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 임상,

[키워드] 95% confidence interval addition all-cause mortality antagonist anti-inflammatory drug Anti-inflammatory drugs article CENTRAL Chemokine receptor comparator control group Controlled controlled trials COVID-19 Critical Critical care CXCL-8 CXCL8 CXCR1 CXCR2 CXCR2 antagonist heterogeneity high risk identify IL-8 In-hospital in-hospital mortality include independent Infection inhibitor Intensive intensive & involved Meta-analysis no difference Odds ratio P -value Patient patients performed Pneumonia Randomized controlled trial Randomized controlled trials randomized trial randomized trials RCT RCTs receptor receptors Reparixin risk of bia risk of infection RoB 2 SARS-CoV-2 SARS-COV-2 infection screened searched Sepsis shown significantly lower suggested survival Treatment trials two groups was used
[DOI] 10.3389/fimmu.2022.932251 PMC 바로가기 [Article Type] Meta-Analysis

Cytopathic SARS-CoV-2 screening on VERO-E6 cells in a large-scale repurposing effort

대규모 용도 변경 노력에서 VERO-E6 세포에 대한 세포변성 SARS-CoV-2 스크리닝

Article

Published on 2022-07-132022-09-11
Journal: Scientific Data [Category] COVID19(2023년), SARS, 신약개발, 치료제,

Outcome of COVID-19 in interstitial lung disease patients treated with anti-inflammatory drugs and antiviral drugs

항염증제 및 항바이러스제 치료를 받는 간질성 폐질환 환자의 코로나19 결과

Article

Published on 2022-07-012022-09-11
Journal: Journal of infection and chemotherapy : official j [Category] 치료제,

[키워드] Affect age and sex anti-inflammatory drug antiviral drug antiviral drugs Antiviral treatment coronavirus disease Coronavirus disease 2019 Corticosteroid corticosteroid therapy Corticosteroids COVID-19 COVID-19 patient COVID-19 patients death Diagnosis evaluate Favipiravir fibrosis honeycomb lung HRCT Idiopathic pulmonary fibrosis ILD immunosuppressive agent Immunosuppressive agents increased risk Interstitial lung disease interstitial pneumonia lung Lung disease medical record medical records mortality rate no statistical difference outcome Patient patients treated patients with COVID-19 proportion pulmonary fibrosis Remdesivir reported risk factor Risk factors selected severe disease Severe patient severe patients treated Univariate analysis
[DOI] 10.1016/j.jiac.2022.04.006 PMC 바로가기 [Article Type] Article